REDWOOD CITY, Calif., June 06, 2016 (GLOBE NEWSWIRE) -- Biotricity, Inc. (OTCQB:BTCY), a healthcare technology company dedicated to delivering innovative, medically relevant biometric remote monitoring solutions, has appointed Thomas Nelson and J. Bernard Rice to its newly formed Board of Advisors (BOA).
"As we continue to look to the future of Biotricity, it's extremely important that the company receives timely insight and knowledge from industry experts who know and understand our business and what benefits both consumers and the medical community. Advisers such as Bernie and Tom will be instrumental to our ongoing evolution, and we are thrilled to welcome these prestigious gentlemen to our group of trusted advisors," commented Waqaas Al-Siddiq, founder, president and CEO of Biotricity.
Former chief operating officer at AARP and consumer healthcare industry expert, Tom Nelson and technology and finance authority, Bernie Rice bring a significant degree of insight and expertise from both the technology and non-profit industries. Joining John Rother and Dr. Danny Sands, the newest members of Biotricity’s BOA will help advise the company as it prepares to unveil its next generation wearable devices.
“Today more than ever, consumers are far more interested in taking a proactive role in their over-all health and disease management,” said Nelson, president of Share Our Strength. “Biotricity aims to revolutionize consumer healthcare by building solutions that enable individuals to manage their conditions and support patient compliance which ultimately leads to health system cost savings. I believe the company’s approach will transform how individuals will monitor and ultimately achieve their health and wellness objectives.”
Rice, a skilled technology and financial thought leader commented: “Chronic illnesses related to lifestyle diseases are on the rise, resulting in increased healthcare costs. This has caused a major shift in the US healthcare market to focus on evidence-based healthcare and overall health-related outcomes. By incorporating medically relevant, clinical-grade data into wearable solutions, these devices can be seamlessly integrated into the world of medicine. I look forward to advising their executive team and helping them to leverage technology in order to address the growing preventative care movement.”
Biotricity’s newest advisory board members include:
- Thomas C. Nelson – Nelson serves as the president of Share Our Strength, a national nonprofit that is ending childhood hunger in America. Nelson oversees the day-to-day management of the organization, including working with the organization’s executive and senior teams to develop and implement its plan for strategic growth.
Prior to joining Share Our Strength in 2011, Nelson was chief operating officer for AARP, where he led the build-out of its state strategy in all 53 US states and territories. He also led the reinvention of the AARP Foundation, which today helps struggling seniors by being a force for change on the most serious issues they face today.
In addition to serving as an adjunct professor at Georgetown University’s McDonough School of Business, Nelson has a long history of service to civic organizations, including his current position on the board of directors of ProInspire. Other board positions include, the board of counselors for the Davis Gerontology School at the University of Southern California; the board of the Certified Financial Planner Board of Standards; and the board of Community Wealth Partners. Nelson holds a Ph.D. from the University of Southern California and an M.A. from Columbia University.
- J. Bernard Rice – Rice is recognized as one of the world’s leading experts in Information Technology. Rice has a wealth of enterprise business experience and significant senior level relationships that are indispensable in developing strategic partnerships. Currently he is supporting a portfolio of companies with leadership capabilities in cybersecurity, green energy, medical technologies, education and real estate.
Rice began his career with IBM and by 1989 he was appointed director of finance, planning and administration for IBM's southern area. In that role, he was responsible for the staff functions of a $3 billion business and he was instrumental in positioning IBM's Southeast Region as the leader in billable services.
Rice became chief financial officer and general partner for the IBM Venture Capital Group in 1993 and then vice president of business development for IBM's Consumer Division in 1998. There he managed projects like IBM's partnership with Berkshire Hathaway and Hallmark for the development of its breakthrough on-line research and learning platforms. Rice also served as chief executive officer of Edmark Inc., the IBM subsidiary that developed innovative educational software for children. Rice holds a B.A. from St. Anselm College and an MBA from Georgia State University and attended the IBM Presidents Program -a special Executive MBA program- at Harvard University.
TWEET THIS: #tech visionary Bernie Rice and #nonprofit expert Tom Nelson joins @biotricity_inc board of advisors #wearables
About Biotricity Inc.
Biotricity is a modern medical technology company focused on delivering innovative, remote biometric monitoring solutions to the medical and consumer markets, including diagnostic and post-diagnostic solutions for chronic conditions and lifestyle improvement. Biotricity’s R&D continues to focus on the preventative healthcare market, with a vision of putting health management into the hands of the individual. The company aims to support the self-management of critical and chronic conditions with the use of innovative solutions to ease the growing burden on the healthcare system. To learn more, visit www.biotricity.com.
Important Cautions Regarding Forward-Looking Statements
Any statements contained in this press release that do not describe historical facts may constitute forward-looking statements. Forward-looking statements may include, without limitation, statements regarding (i) the plans and objectives of management for future operations, including plans or objectives relating to the design, development and commercialization of bioflux or any of the Company’s other proposed products or services, (ii) a projection of income (including income/loss), earnings (including earnings/loss) per share, capital expenditures, dividends, capital structure or other financial items, (iii) the Company's future financial performance and (iv) the assumptions underlying or relating to any statement described in points (i), (ii) or (iii) above. Such forward-looking statements are not meant to predict or guarantee actual results, performance, events or circumstances and may not be realized because they are based upon the Company's current projections, plans, objectives, beliefs, expectations, estimates and assumptions and are subject to a number of risks and uncertainties and other influences, many of which the Company has no control over. Actual results and the timing of certain events and circumstances may differ materially from those described by the forward-looking statements as a result of these risks and uncertainties. Factors that may influence or contribute to the inaccuracy of the forward-looking statements or cause actual results to differ materially from expected or desired results may include, without limitation, the Company's inability to obtain additional financing, the significant length of time and resources associated with the development of its products and related insufficient cash flows and resulting illiquidity, the Company's inability to expand the Company's business, significant government regulation of medical devices and the healthcare industry, lack of product diversification, existing or increased competition, results of arbitration and litigation, stock volatility and illiquidity, and the Company's failure to implement the Company's business plans or strategies. These and other factors are identified and described in more detail in the Company's filings with the SEC. The Company assumes no obligation to update any forward-looking statements in order to reflect any event or circumstance that may arise after the date of this release.
Media Contacts McCoin & Smith Communications Inc. Chris McCoin, Chris@mccoinsmith.com, 508-429-5988 Richard Smith, email@example.com, 978-433-3304 Investor Relations: Michael Koehler Liolios Group, Inc. BTCY@liolios.com 949-574-3860